Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Medtronic plc announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc.
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”
The board of directors of Medtronic plc approved an 8 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.54 per ordinary share.
Galapagos NV announces a share capital increase arising from warrant exercises.
This week marked initial public offering news from six biopharma companies. Here’s a look.
Lonza reports restated 2018 financials for sales, CORE EBITDA and CORE EBIT
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results as of and for the year ended December 31, 2018 as well as operative highlights.
Evotec SE announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities.
Proceeds will facilitate clinical development of Imcyse’s technology in type 1 diabetes, multiple sclerosis and other indications
Galapagos NV received a transparency notification from The Capital Group Companies, Inc.